Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

Eitemau Tebyg

• Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
  gan: Kroonen, Marjolein Y. A. M., et al.
  Cyhoeddwyd: (2020)
• Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
  gan: Koomen, Jeroen V., et al.
  Cyhoeddwyd: (2018)
• Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials
  gan: Idzerda, Nienke M A, et al.
  Cyhoeddwyd: (2019)
• Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
  gan: de Zeeuw, Dick, et al.
  Cyhoeddwyd: (2020)
• Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
  gan: Koomen, Jeroen V., et al.
  Cyhoeddwyd: (2020)